JP2003137789A - Nitrogen monoxide eliminator - Google Patents

Nitrogen monoxide eliminator

Info

Publication number
JP2003137789A
JP2003137789A JP2001337858A JP2001337858A JP2003137789A JP 2003137789 A JP2003137789 A JP 2003137789A JP 2001337858 A JP2001337858 A JP 2001337858A JP 2001337858 A JP2001337858 A JP 2001337858A JP 2003137789 A JP2003137789 A JP 2003137789A
Authority
JP
Japan
Prior art keywords
nitric oxide
filter
glucosamine
active ingredient
chitosan
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2001337858A
Other languages
Japanese (ja)
Other versions
JP4373634B2 (en
Inventor
Kazuaki Kikuchi
数晃 菊地
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yaizu Suisan Kagaku Kogyo Co Ltd
Original Assignee
Yaizu Suisan Kagaku Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yaizu Suisan Kagaku Kogyo Co Ltd filed Critical Yaizu Suisan Kagaku Kogyo Co Ltd
Priority to JP2001337858A priority Critical patent/JP4373634B2/en
Publication of JP2003137789A publication Critical patent/JP2003137789A/en
Application granted granted Critical
Publication of JP4373634B2 publication Critical patent/JP4373634B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Saccharide Compounds (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Treating Waste Gases (AREA)
  • Gas Separation By Absorption (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a nitrogen monoxide eliminator that has high safety to human bodies and can effectively eliminate nitrogen monoxide. SOLUTION: This nitrogen monoxide eliminator contains, as an active ingredient, at least one selected from glucosamine, chitosan oligosaccharides with a polymerization degree of 2-10, low-molecular-weight chitosan with a polymerization degree of 11-100 and their salts. The nitrogen monoxide eliminator is preferably used by adding to at least one selected from drinks, foods, medicines or cosmetics. Particularly, in the cases that glucosamine and/or salts thereof are used as an active ingredient, they may be used as one component for tobacco filers, air cleaner filters, air conditioner filters and car mufflers.

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【発明の属する技術分野】本発明は、甲殻類の殻等から
得られるグルコサミン等を有効成分として含有する安全
性の高い一酸化窒素消去剤に関する。
TECHNICAL FIELD The present invention relates to a highly safe nitric oxide scavenger containing glucosamine or the like obtained from shells of crustaceans as an active ingredient.

【0002】[0002]

【従来の技術】一酸化窒素(以下、NOという)は、大
気汚染物質として問題となっている窒素酸化物(NO
x)の一種であり、大気中で酸化されて二酸化窒素(N
2)になる。二酸化窒素は、高濃度で呼吸器に影響を
及ぼすほか、酸性雨や化学オキシダントの原因物質にな
ると言われている。また、空気中のNOは、酸化剤とし
て働き、皮脂に含まれる不飽和脂肪酸等を攻撃して、肌
荒れ等を引き起こす原因となる可能性も指摘されている
(大久保洋一ら:大気汚染学会誌,25(3),212-220,19
90)。
2. Description of the Related Art Nitric oxide (hereinafter referred to as NO) is a nitrogen oxide (NO) which has been a problem as an air pollutant.
x), which is oxidized in the atmosphere to produce nitrogen dioxide (N
O 2 ). Nitrogen dioxide is said to be a cause of acid rain and chemical oxidants, in addition to affecting respiratory organs at high concentrations. It has also been pointed out that NO in the air may act as an oxidant and attack unsaturated fatty acids contained in sebum to cause rough skin (Yoichi Okubo et al., Journal of Air Pollution Society, 25 (3), 212-220, 19
90).

【0003】NOの発生原因は、主として石油等の化石
燃料の燃焼によるものであり、工場、自動車、家庭等か
ら排出されている。また、より身近な例としてタバコの
煙中にも存在することが知られている(Shinagawa, K.
et al: Biochem. Biophys.Res. Commun, 253, 99−10
3, 1998)。
The cause of generation of NO is mainly due to combustion of fossil fuel such as petroleum and is emitted from factories, automobiles, households and the like. It is also known to be present in cigarette smoke as a more familiar example (Shinagawa, K.
et al: Biochem. Biophys. Res. Commun, 253, 99-10
3, 1998).

【0004】一方、NOは生体内にも存在することが知
られている。生体内のNO(以下、生体内NOという)
は、L−アルギニン、NADPH、テトラヒドロビオプ
テリン、カルモジュリン等を基質としてNO合成酵素
(以下、NOSという)により作られ、極めて重要な生
理活性分子として機能している。例えば、血管内皮由来
弛緩因子(EDRF)の正体はNOであり、その他、神
経系における情報伝達物質や免疫系での異物攻撃の役割
を担っていることが知られている。
On the other hand, NO is known to exist in the living body. NO in vivo (hereinafter referred to as NO in vivo)
Is produced by NO synthase (hereinafter referred to as NOS) using L-arginine, NADPH, tetrahydrobiopterin, calmodulin and the like as substrates, and functions as an extremely important physiologically active molecule. For example, the true identity of vascular endothelium-derived relaxing factor (EDRF) is NO, and it is known that it plays a role of a foreign substance attack in a signal transmitter in the nervous system and in the immune system.

【0005】生体内NOの作用には二面性があり、産生
量が多すぎても少なすぎても疾病に結びつく。例えば、
敗血症は、過剰なNO産生によって血管が拡張されて急
激な血圧低下によりショック状態(敗血症性ショック)
を引き起こすことが知られている。また、過剰に産生し
たNOは、マクロファージが産生する活性酸素と反応し
て強力な酸化剤となり、神経細胞障害や動脈硬化を引き
起こす原因となったり、マクロファージ等の免疫細胞自
身を破壊する可能性も指摘されている。
The action of NO in the living body has two sides, and if the amount produced is too large or too small, it will lead to diseases. For example,
Sepsis is a shock state (septic shock) due to a rapid decrease in blood pressure due to the expansion of blood vessels due to excessive NO production.
Is known to cause. In addition, excessively produced NO reacts with active oxygen produced by macrophages to become a strong oxidant, which may cause nerve cell damage and arteriosclerosis, or destroy immune cells themselves such as macrophages. It has been pointed out.

【0006】過剰に産生された生体内NOを低減する手
段として、NOSを不活性化する阻害剤(以下、NOS
阻害剤という)やNOと速やかに反応する消去剤(以
下、NO消去剤という)等の使用が挙げられる(吉村哲
彦著:「NO(一酸化窒素)宇宙から細胞まで」、p.11
3−134、共立出版(1998))。このようなNOS阻害剤
としては、Nω−モノメチル−L−アルギニン、Nω
ジメチル−L−アルギニン、Nω−ニトロ−L−アルギ
ニン等のL−アルギニン誘導体やアミノグアニジンやS
−エチルイソチオウレア等のアルギニン類似化合物が挙
げられる。また、NO消去剤としては、例えば、ジエチ
レントリアミン5酢酸の鉄錯体、デスフェリオキサミン
の鉄錯体、ヒドロキソコバラミン等が挙げられる。
[0006] As a means of reducing the excessively produced in vivo NO, an inhibitor that inactivates NOS (hereinafter referred to as NOS
Inhibitors) and scavengers that react rapidly with NO (hereinafter referred to as NO scavengers) can be used (Tetsuhiko Yoshimura: "From NO (nitric oxide) universe to cells", p.11.
3-134, Kyoritsu Shuppan (1998)). Such NOS inhibitors, N omega - monomethyl -L- arginine, N omega -
Dimethyl -L- arginine, N ω - L- arginine derivative nitro -L- arginine and aminoguanidine or S
-Arginine analogs such as ethylisothiourea. Further, examples of the NO eliminator include an iron complex of diethylenetriaminepentaacetic acid, an iron complex of desferrioxamine, and hydroxocobalamin.

【0007】[0007]

【発明が解決しようとする課題】しかしながら、上記の
ようなNOS阻害剤を投与した臨床的な試みにおいて
は、症状の改善にはつながるものの、血圧の上昇、臓器
の血流低下・障害等の様々な副作用を引き起こすという
問題があることが分かった。また、上記のようなNO消
去剤は、生理的に恒常性を維持しているNOまでも除い
てしまう可能性があり、生体への適用については未知数
であった。
However, in clinical trials in which the above-mentioned NOS inhibitor is administered, although the symptoms are improved, there are various causes such as an increase in blood pressure, a decrease in blood flow in organs, and a disorder. It turns out that there is a problem of causing various side effects. Further, the NO scavenger as described above may remove even NO that maintains physiological homeostasis, and its application to living organisms has been unknown.

【0008】したがって、本発明の目的は、人体に対す
る安全性が高く、効果的に一酸化窒素を除去できる一酸
化窒素消去剤を提供することにある。
Therefore, an object of the present invention is to provide a nitric oxide scavenger which is highly safe for the human body and can effectively remove nitric oxide.

【0009】[0009]

【問題を解決するための手段】本発明者は、グルコサミ
ン、キトサンオリゴ糖、低分子キトサン等の生理活性を
研究する過程で、グルコサミン及びキトサンオリゴ糖が
強い一酸化窒素消去能を有することを見い出し、この知
見に基いて本発明を完成するに至った。
[Means for Solving the Problem] In the process of studying physiological activities of glucosamine, chitosan oligosaccharides, low molecular weight chitosan, etc., the present inventors found that glucosamine and chitosan oligosaccharides have strong nitric oxide scavenging ability. The present invention has been completed based on this finding.

【0010】すなわち、本発明の一酸化窒素消去剤は、
グルコサミン、重合度2〜10のキトサンオリゴ糖、重
合度11〜100の低分子キトサン及びそれらの塩から
選ばれた少なくとも1種を有効成分として含有すること
を特徴とする。
That is, the nitric oxide scavenger of the present invention is
It is characterized by containing at least one selected from glucosamine, chitosan oligosaccharide having a degree of polymerization of 2 to 10, low molecular weight chitosan having a degree of polymerization of 11 to 100, and salts thereof as an active ingredient.

【0011】本発明によれば、天然物由来の成分である
グルコサミン、キトサンオリゴ糖、低分子キトサン等を
有効成分として含有させることにより、効果的に一酸化
窒素を除去でき、例えば飲食品、医薬品に添加して摂取
しても、副作用等のない安全性の高い一酸化窒素消去剤
を提供できる。
According to the present invention, by incorporating glucosamine, chitosan oligosaccharide, low molecular weight chitosan, etc., which are naturally derived ingredients, as an active ingredient, nitric oxide can be effectively removed. It is possible to provide a highly safe nitric oxide scavenger without side effects even when added to and ingested.

【0012】また、本発明の一酸化窒素消去剤は、中性
pH域においても水溶性であるので、飲食品、医薬品等
に添加する場合に容易に他の原料と均一に混合でき、経
口で摂取した際には体内への吸収性が高い。
Since the nitric oxide scavenger of the present invention is water-soluble even in the neutral pH range, it can be easily mixed uniformly with other raw materials when added to foods and drinks, pharmaceuticals, etc. Highly absorbed by the body when ingested.

【0013】本発明の一酸化窒素消去剤は、好ましくは
飲食品、医薬品、又は化粧品から選ばれた1種に添加し
て用いられる。また、飲食品の場合には、硝酸塩又は亜
硝酸塩系の発色剤又は保存剤を含有する飲食品に特に効
果的である。
The nitric oxide scavenger of the present invention is preferably used by adding it to one selected from foods and drinks, pharmaceuticals, or cosmetics. In the case of food and drink, it is particularly effective for food and drink containing a nitrate- or nitrite-based color former or preservative.

【0014】この一酸化窒素消去剤を添加した飲食品や
医薬品を摂取あるいは投与することにより、過剰な生体
内NOを安全かつ効果的に除去でき、例えば敗血症性シ
ョック、糖尿病合併症、神経細胞障害、炎症、気管支喘
息等の予防やこれらの症状改善、狭心症やインポテンツ
の治療薬を服用する際の副作用の低減等の効果が期待で
きる。
Ingestion or administration of foods and drinks or pharmaceuticals to which this nitric oxide scavenger is added can safely and effectively remove excess NO in the living body. For example, septic shock, diabetic complications, and nerve cell disorders. It can be expected to have effects such as prevention of inflammation, bronchial asthma and the like, improvement of these symptoms, and reduction of side effects when taking a remedy for angina and impotence.

【0015】また、発色剤及び保存剤として飲食品に添
加される硝酸塩や亜硝酸塩は、細菌の作用により還元さ
れてNOとなり、該飲食品中のアミン(アミノ酸類)と
反応して発ガン性物質であるニトロソアミンを生成する
ことが分かっているが、本発明の一酸化窒素消去剤を添
加することにより、ニトロソアミンの生成防止効果が期
待できる。
Further, nitrates and nitrites added to foods and drinks as color formers and preservatives are reduced to NO by the action of bacteria and react with amines (amino acids) in the foods and drinks to cause carcinogenicity. It is known that nitrosamine, which is a substance, is produced, but by adding the nitric oxide scavenger of the present invention, a nitrosamine production preventing effect can be expected.

【0016】更に、この一酸化窒素消去剤を添加した化
粧品を皮膚に塗布することにより、空気中のNOによる
皮膚の酸化変性を抑制して、肌荒れ、くすみ等の防止効
果が期待できる。
Further, by applying the cosmetic containing the nitric oxide scavenger to the skin, the oxidative modification of the skin due to NO in the air can be suppressed, and the effect of preventing rough skin, dullness, etc. can be expected.

【0017】本発明の一酸化窒素消去剤のうち、特にグ
ルコサミン及び/又はその塩を有効成分として含有する
ものは、タバコ用フィルター、空気清浄器用フィルタ
ー、エアコンディショナー用フィルター又は自動車のマ
フラー用フィルターから選ばれた1種の成分として好適
に用いられる。
Among the nitric oxide scavengers of the present invention, those containing glucosamine and / or a salt thereof as an active ingredient may be selected from filters for cigarettes, filters for air purifiers, filters for air conditioners or filters for mufflers of automobiles. It is preferably used as one selected component.

【0018】この一酸化窒素消去剤を添加した上記フィ
ルターは、タバコの煙、空気又は排気ガス中に含まれる
NO量を効果的に低減することができるので、空気中の
NOによる健康への悪影響を軽減することができる。
The above-mentioned filter to which the nitric oxide scavenger is added can effectively reduce the amount of NO contained in cigarette smoke, air or exhaust gas, and therefore adversely affects the health of NO in the air. Can be reduced.

【0019】[0019]

【発明の実施の形態】本発明の一酸化窒素消去剤の有効
成分であるグルコサミンは、糖タンパク質、糖脂質、ム
コ多糖等の生体成分中に分布する天然アミノ糖であり、
工業的にはカニ、エビ、オキアミ等の甲殻類やイカの軟
骨に含まれるキチンを、酸又は酵素で加水分解すること
により調製できる。また、グルコサミンは、遊離体であ
ってもよく、塩を形成していてもよい。グルコサミン塩
としては、例えば、塩酸塩、硫酸塩等が挙げられる。こ
れらのグルコサミンやその塩は、市販のものを用いるこ
とができる。
BEST MODE FOR CARRYING OUT THE INVENTION Glucosamine, which is an active ingredient of the nitric oxide scavenger of the present invention, is a natural amino sugar distributed in biological components such as glycoproteins, glycolipids and mucopolysaccharides.
Industrially, it can be prepared by hydrolyzing chitin contained in cartilage of crustaceans such as crab, shrimp and krill and cartilage of squid with an acid or an enzyme. Further, glucosamine may be in a free form or may form a salt. Examples of the glucosamine salt include hydrochloride, sulfate and the like. As these glucosamine and salts thereof, commercially available products can be used.

【0020】本発明の一酸化窒素消去剤の有効成分であ
る重合度2〜10のキトサンオリゴ糖、重合度11〜1
00の低分子キトサンは、キチンを脱アセチル化して得
られるキトサンを酸又は酵素で加水分解することにより
調製できる。また、上記キトサンオリゴ糖並びに低分子
キトサンは、遊離体であってもよく、塩を形成していて
もよい。キトサンオリゴ糖並びに低分子キトサンの塩と
しては、例えば、塩酸塩、乳酸塩、酢酸塩、硫酸塩、ク
エン酸塩、アスコルビン酸塩、リンゴ酸塩、コハク酸
塩、アジピン酸塩、グルコン酸塩、酒石酸塩等が挙げら
れる。
Chitosan oligosaccharides having a degree of polymerization of 2 to 10, which are the active ingredients of the nitric oxide scavenger of the present invention, and a degree of polymerization of 11 to 1
The low molecular weight chitosan of 00 can be prepared by hydrolyzing chitosan obtained by deacetylating chitin with an acid or an enzyme. The chitosan oligosaccharide and low molecular weight chitosan may be in the free form or may form a salt. Examples of salts of chitosan oligosaccharides and low molecular weight chitosan include, for example, hydrochloride, lactate, acetate, sulfate, citrate, ascorbate, malate, succinate, adipate, gluconate, Examples thereof include tartrate salts.

【0021】また、上記のような重合度のキトサンオリ
ゴ糖並びに低分子キトサンは、体内への吸収性が高く、
経口摂取した際に効果的に生体内NOを消去できること
が期待される。また、中性pH域においても水溶性であ
るので、飲食品、医薬品等に添加する場合に、容易に他
の原料と均一に混合でき、加工性に優れている。これら
のキトサンオリゴ糖並びに低分子キトサン、及びそれら
の塩は、市販のものを用いることができる。
Further, chitosan oligosaccharides and low molecular weight chitosan having the above-mentioned degree of polymerization have high absorbability into the body,
It is expected that NO in vivo can be effectively eliminated when taken orally. Further, since it is water-soluble even in the neutral pH range, it can be easily and uniformly mixed with other raw materials when it is added to foods and drinks, pharmaceuticals, etc., and has excellent processability. Commercially available chitosan oligosaccharides, low molecular weight chitosan, and salts thereof can be used.

【0022】本発明の一酸化窒素消去剤におけるグルコ
サミン、重合度2〜10のキトサンオリゴ糖、重合度1
1〜100の低分子キトサン及びそれらの塩から選ばれ
た少なくとも1種(以下、有効成分という)の含有量
は、0.1質量%以上が好ましく、10質量%以上がよ
り好ましく、20質量%以上が特に好ましい。
Glucosamine, a chitosan oligosaccharide having a degree of polymerization of 2 to 10, a degree of polymerization of 1 in the nitric oxide scavenger of the present invention.
The content of at least one selected from low molecular weight chitosan of 1 to 100 and salts thereof (hereinafter referred to as an active ingredient) is preferably 0.1% by mass or more, more preferably 10% by mass or more, and 20% by mass. The above is particularly preferable.

【0023】天然物由来の成分であるグルコサミンや、
キトサンオリゴ糖や、低分子キトサンは、従来から健康
食品や医薬品の原料として広範に利用されており、副作
用の少ない安全な物質であることが分かっている。
Glucosamine, a component derived from natural products,
Chitosan oligosaccharides and low molecular weight chitosan have been widely used as raw materials for health foods and pharmaceuticals, and are known to be safe substances with few side effects.

【0024】本発明の一酸化窒素消去剤は、上記有効成
分の他に、賦形剤、ミネラル類、ビタミン類、糖類、香
料等を適宜含むことができる。また、その製品形態は、
特に制限されず、錠剤、粉末、顆粒、溶液、カプセル剤
等が挙げられる。
The nitric oxide scavenger of the present invention may appropriately contain excipients, minerals, vitamins, sugars, flavors and the like in addition to the above-mentioned active ingredients. In addition, the product form is
It is not particularly limited, and examples thereof include tablets, powders, granules, solutions, capsules and the like.

【0025】本発明の一酸化窒素消去剤は、飲食品、医
薬品、又は化粧品から選ばれた1種に添加して用いるこ
とができる。
The nitric oxide scavenger of the present invention can be used by adding it to one selected from foods and drinks, pharmaceuticals, and cosmetics.

【0026】例えば、飲食品用途に用いる場合、その添
加量は、上記有効成分換算で1日当たり0.1〜100
0mg摂取できる量が好ましく、10〜1000mg摂
取できる量がより好ましい。
For example, when it is used for food and drink, the amount added is 0.1 to 100 per day in terms of the above-mentioned active ingredients.
The amount that can be ingested by 0 mg is preferable, and the amount that can be ingested by 10 to 1000 mg is more preferable.

【0027】また、医薬品用途に用いる場合、その有効
投与量は、経口投与の場合は、1日当たり上記有効成分
換算で0.1〜1000mgであり、より好ましくは
0.1〜100mgである。また、静注及び筋注する場
合は、1日当たり上記有効成分換算で0.01mg〜1
00mgであり、より好ましくは0.1〜10mgであ
る。
When used for pharmaceuticals, the effective dose for oral administration is 0.1 to 1000 mg, more preferably 0.1 to 100 mg, calculated as the above-mentioned active ingredient per day. In the case of intravenous injection and intramuscular injection, 0.01 mg to 1 in terms of the above-mentioned active ingredient per day.
It is 00 mg, more preferably 0.1 to 10 mg.

【0028】本発明の一酸化窒素消去剤を添加した飲食
品や医薬品を、摂取あるいは投与することにより、過剰
な生体内NOを安全かつ効果的に消去できることが期待
される。したがって、過剰な生体内NOの生成によって
引き起こされる疾病、例えば敗血症性ショック、糖尿病
合併症、神経細胞障害、炎症、気管支喘息等の予防やこ
れらの症状の改善、狭心症やインポテンツの治療薬を服
用する際の副作用の低減等の効果が期待できる。
It is expected that excessive in vivo NO can be safely and effectively eliminated by ingesting or administering the food or drink or the drug to which the nitric oxide eliminating agent of the present invention is added. Therefore, it is necessary to prevent diseases such as septic shock, diabetic complications, nerve cell disorders, inflammation, bronchial asthma and the like caused by excessive production of NO in the body, improve these symptoms, and treat angina and impotence. Effects such as side effects when taking the drug can be expected.

【0029】また、硝酸塩や亜硝酸塩系の発色剤又は保
存剤を含有する飲食品(例えばハム、サラミ、ソーセー
ジ、ベーコン、タラコ、すじこ等)に、本発明の一酸化
窒素消去剤を添加することにより、ニトロソアミンの生
成防止効果が期待できる。
Further, the nitric oxide scavenger of the present invention may be added to foods and drinks (eg, ham, salami, sausages, bacon, tarako, sashiko etc.) containing a nitrate or nitrite type color former or preservative. Therefore, an effect of preventing the generation of nitrosamine can be expected.

【0030】また、化粧品用途に用いる場合は、その添
加量は、上記有効成分換算で0.01〜10質量%が好
ましく、0.01〜1.0質量%がより好ましい。
When it is used for cosmetics, its addition amount is preferably 0.01 to 10% by mass, more preferably 0.01 to 1.0% by mass in terms of the above-mentioned active ingredient.

【0031】本発明の一酸化窒素消去剤を添加した化粧
品を使用することにより、空気中のNOによる皮脂に含
まれる不飽和脂肪酸やタンパク質の酸化変性を抑制し、
肌荒れ、くすみ等を防止する効果が期待できる。
By using the cosmetics to which the nitric oxide scavenger of the present invention is added, oxidative denaturation of unsaturated fatty acids and proteins contained in sebum due to NO in the air is suppressed,
The effect of preventing rough skin and dullness can be expected.

【0032】また、本発明の一酸化窒素消去剤は、有効
成分としてグルコサミン及び/又はその塩を含有する場
合、タバコ用フィルター、空気清浄器用フィルター、エ
アコンディショナー用フィルター又は自動車のマフラー
用フィルターから選ばれた1種の成分として好適に用い
ることができる。具体的には、一酸化窒素消去剤を粉末
のまま、あるいは適当な担体と共にフィルターに充填す
る、あるいは半透膜性のポリマーで被覆・固定化してマ
イクロカプセルとして用いることができる。
Further, the nitric oxide scavenger of the present invention, when it contains glucosamine and / or its salt as an active ingredient, is selected from a cigarette filter, an air purifier filter, an air conditioner filter or an automobile muffler filter. It can be preferably used as one component. Specifically, the nitric oxide scavenger can be used as a microcapsule as a powder, or by filling it in a filter with an appropriate carrier, or by coating and immobilizing it with a semipermeable polymer.

【0033】なお、本発明におけるタバコ用フィルター
とは、市販のタバコに別途装着して使用するフィルタ
ー、市販のフィルター付きタバコにおけるフィルターを
意味する。このタバコ用フィルターを用いることによ
り、タバコの煙(吸引煙)中のNO量を低減することが
できる。
The cigarette filter in the present invention means a filter which is separately attached to a commercially available cigarette and used, or a filter in a commercially available cigarette with a filter. By using this cigarette filter, the amount of NO in cigarette smoke (suction smoke) can be reduced.

【0034】タバコ用フィルターに一酸化窒素消去剤を
充填する場合、該フィルター1個当たりの充填量は、グ
ルコサミン及び/又はその塩換算で0.1〜100mg
が好ましく、10〜50mgがより好ましい。
When a cigarette filter is filled with a nitric oxide scavenger, the filling amount per filter is 0.1 to 100 mg in terms of glucosamine and / or its salt.
Is preferred, and 10 to 50 mg is more preferred.

【0035】[0035]

【実施例】以下、実施例を挙げて本発明を更に詳細に説
明する。
EXAMPLES The present invention will be described in more detail with reference to examples.

【0036】実施例1 被験物質として、グルコサミン塩酸塩、キトサンオリゴ
糖塩酸塩、N−アセチルグルコサミン、キチンオリゴ
糖、セロオリゴ糖、マルトオリゴ糖を用いて、NO消去
能の測定を行なった。
Example 1 As test substances, glucosamine hydrochloride, chitosan oligosaccharide hydrochloride, N-acetylglucosamine, chitin oligosaccharide, cellooligosaccharide and maltooligosaccharide were used to measure the NO scavenging ability.

【0037】また、NO発生試薬として1−hydroxy−2
−oxo−3−(N−3−methyl−3−aminopropyl)−3−methy
l−1−triazene(以下、NOC−7という。同仁化学
(株)製)を、NO用スピントラップ剤として2−(4−c
arboxyphenyl)−4,4,5,5−tetramethylimidazoline−1
−oxyl−3−oxide sodium salt(以下、C−PTIOとい
う。ラボテック(株)製)を用い、各被験物質は、各々
2.0%(w/v)の濃度となるように0.1Mリン酸
緩衝液(pH7.4)に溶解して用いた。
Further, 1-hydroxy-2 is used as an NO generating reagent.
-Oxo-3- (N-3-methyl-3-aminopropyl) -3-methy
l-1-triazene (hereinafter referred to as NOC-7, manufactured by Dojindo Co., Ltd.) was used as 2- (4-c) as a spin trap agent for NO.
arboxyphenyl) -4,4,5,5-tetramethylimidazoline-1
-Oxyl-3-oxide sodium salt (hereinafter referred to as C-PTIO, manufactured by Labotech Co., Ltd.) was used, and each test substance was adjusted to a concentration of 2.0% (w / v) with 0.1 M phosphorus. It was dissolved in an acid buffer (pH 7.4) before use.

【0038】NO消去能の測定は、文献(Noda et a
l.:Res. Commun. Mol. Pathol. Pharmacol., 96, 115-
124, 1997)に記載された方法にしたがって行なった。
The NO scavenging ability is measured in the literature (Noda et a
l .: Res. Commun. Mol. Pathol. Pharmacol., 96, 115-
124, 1997).

【0039】すなわち、試験管に0.1Mリン酸緩衝液
(pH7.4)を140μLと、被験物質溶液20μL
と、0.1mM C−PTIO(リン酸緩衝液の溶液)とを入
れて混合した後、0.1mM NOC−7(0.1N N
aOHの溶液)20μLを混合して、直ちに扁平石英セ
ル(商品名「ES−LC12」、日本電子株式会社製、
以下同じ)に採取し、電子スピン共鳴装置(以下、ES
R装置という。商品名「JES−FR30」、日本電子株式会
社製、以下同じ)にセットした。
That is, 140 μL of 0.1 M phosphate buffer (pH 7.4) and 20 μL of test substance solution were placed in a test tube.
And 0.1 mM C-PTIO (phosphate buffer solution) were added and mixed, and then 0.1 mM NOC-7 (0.1 N N
20 μL of a solution of aOH was mixed and immediately a flat quartz cell (trade name “ES-LC12”, manufactured by JEOL Ltd.,
The same shall apply hereinafter) and the electron spin resonance apparatus (hereinafter, ES
R device. The product name "JES-FR30", manufactured by JEOL Ltd., the same applies hereinafter).

【0040】そして、NOC−7を混合してから正確に
15分後、C−PTIOがNOをトラップする時に検出され
るC−PTIのシグナル強度を指標としてNO発生量を測定
した。なお、内部標準物質にはMnOを用いた。
Exactly 15 minutes after mixing NOC-7, the amount of NO generated was measured using the signal intensity of C-PTI detected when C-PTIO traps NO as an index. MnO was used as the internal standard substance.

【0041】被験物質溶液の代わりにリン酸緩衝液を使
用した時のC−PTIシグナル強度を100%(コントロー
ル)として、各被験物質を添加した時のNO相対量を計
算し、各被験物質のNO消去能を調べた。その結果を図
1に示す。
With the C-PTI signal intensity when a phosphate buffer solution was used instead of the test substance solution as 100% (control), the relative amount of NO when each test substance was added was calculated and The NO scavenging ability was investigated. The result is shown in FIG.

【0042】図1から、N−アセチルグルコサミン、キ
チンオリゴ糖、セロオリゴ糖、マルトオリゴ糖等の中性
糖を添加した場合、NO残存率はコントロールと大差が
なく、NO消去能は低いか、全く認められないのに対し
て、グルコサミン塩酸塩又はキトサンオリゴ糖塩酸塩を
添加した場合は、それぞれ98.5%、95.8%のN
Oが消去され、アミノ糖類は非常に強いNO消去能を有
することが分かる。
From FIG. 1, when neutral sugars such as N-acetylglucosamine, chitin oligosaccharides, cellooligosaccharides, and maltooligosaccharides were added, the NO residual ratio was not much different from the control, and the NO elimination ability was low or not observed at all. On the other hand, when glucosamine hydrochloride or chitosan oligosaccharide hydrochloride was added, 98.5% and 95.8% N, respectively were obtained.
It can be seen that O is eliminated and the amino sugar has a very strong NO eliminating ability.

【0043】実施例2 結晶セルロースを担体として、下記配合割合で各原料を
混合し、この粉末0.5gをプラスチックの円筒(直径
5mm×長さ80mm)に充填してタバコ用フィルター
を作製した。また、コントロールとして結晶セルロース
(担体)のみを充填したフィルターを作製した。
Example 2 Using crystalline cellulose as a carrier, the respective raw materials were mixed in the following blending ratio, and 0.5 g of this powder was filled in a plastic cylinder (diameter 5 mm × length 80 mm) to prepare a cigarette filter. As a control, a filter filled with crystalline cellulose (carrier) was prepared.

【0044】 ・タバコフィルターの組成(質量%) 結晶セルロース 79.9 グルコサミン塩酸塩 20.0 活性炭 0.1 得られた各フィルターを市販タバコの吸い口に付けて、
吸引しながらタバコに点火し、点火箇所から3cmの長
さまで燃焼させ、フィルターを通過した吸引煙をスピン
トラップ剤の入った試験管にそれぞれ捕集した。なお、
スピントラップ剤には、N−metyl−D−glucamine−dith
iocarbamate(以下、MGDという。ラボテック(株)
から購入)と硫酸鉄(II)水溶液とを混合して調製し
た(MGD)2−Fe2+複合体を用いた。具体的には、
50mM MGD溶液(0.1Mリン酸緩衝液(pH
7.4))1.0mLと、50mM硫酸鉄(II)水溶
液0.2mLとを混合して直ちに使用した。
Tobacco filter composition (% by mass) Crystalline cellulose 79.9 Glucosamine hydrochloride 20.0 Activated carbon 0.1 Each of the obtained filters was attached to the mouthpiece of a commercially available cigarette,
The cigarette was ignited while being sucked, and was burned to a length of 3 cm from the ignition point, and the sucked smoke that passed through the filter was collected in each test tube containing the spin trap agent. In addition,
The spin trap agent is N-metyl-D-glucamine-dith.
iocarbamate (hereinafter referred to as MGD. Labtech Co., Ltd.)
(MGD) 2 -Fe 2+ complex prepared by mixing an aqueous solution of iron (II) sulfate. In particular,
50 mM MGD solution (0.1 M phosphate buffer (pH
7.4)) 1.0 mL and 0.2 mL of 50 mM iron (II) sulfate aqueous solution were mixed and used immediately.

【0045】30分後に各捕集液を扁平石英セルに採取
してESR装置にセットし、(MGD)2−Fe2+−N
O複合体のスペクトル強度をそれぞれ測定した。そし
て、コントロールのフィルターを通過した吸引煙中のN
O量を100%として、各フィルターを通過した吸引煙
中のNO量を計算した。その結果を図2に示す。
After 30 minutes, each of the collected liquids was collected in a flat quartz cell and set in an ESR device, and (MGD) 2 —Fe 2+ —N
The spectral intensity of the O complex was measured. Then, the N in the sucked smoke that has passed through the control filter
The amount of O was set to 100% and the amount of NO in the suction smoke that passed through each filter was calculated. The result is shown in FIG.

【0046】図2から、グルコサミン塩酸塩を充填した
フィルターを通過した吸引煙中のNO量は、コントロー
ルに比べて約30%減少していることが分かる。すなわ
ち、グルコサミン塩酸塩には、タバコの煙中のNOを低
減する効果があることが明らかとなった。
From FIG. 2, it can be seen that the amount of NO in the suction smoke that has passed through the filter filled with glucosamine hydrochloride is reduced by about 30% as compared with the control. That is, it was revealed that glucosamine hydrochloride has an effect of reducing NO in cigarette smoke.

【0047】実施例3 以下に示すような配合によって、本発明の一酸化窒素消
去剤を用いた錠菓、化粧品、錠剤、静注用脂肪乳剤をそ
れぞれ製造した。
Example 3 Tablet confectionery, cosmetics, tablets, and a fat emulsion for intravenous injection using the nitric oxide scavenger of the present invention were produced by the following formulations.

【0048】 錠菓(一錠1.5g当たり) グルコサミン塩酸塩 400mg キトサンオリゴ糖塩酸塩 200mg レモン果汁粉末 200mg ブドウ糖 50mg 結晶セルロース 650mg 化粧品(ファンデーション) 大豆リン脂質 50.0質量% グリセリン 10.0質量% グルコサミン塩酸塩 5.0質量% 海草エキス 3.0質量% ヒアルロン酸 0.5質量% 紫外線吸収剤 適量 注射用水 全体を100としたときの残余 錠剤(200mg/錠) 結晶セルロース 140mg ジエチレントリアミン五酢酸−鉄錯体 10mg グルコサミン塩酸塩 50mg 静注用脂肪乳剤 精製大豆リン脂質 10.0質量% キトサンオリゴ糖 1.0質量% D−マンニトール 5.0質量% 注射用水 84.0質量%[0048]   Tablet confectionery (per tablet 1.5g)     Glucosamine hydrochloride 400mg     Chitosan oligosaccharide hydrochloride 200mg     Lemon juice powder 200mg     Glucose 50mg     Crystalline cellulose 650mg   Cosmetics (foundation)     Soybean phospholipids 50.0% by mass     Glycerin 10.0% by mass     Glucosamine hydrochloride 5.0 mass%     Seaweed extract 3.0 mass%     Hyaluronic acid 0.5% by mass     UV absorber suitable amount     Remaining amount of water for injection as 100   Tablet (200 mg / tablet)     Crystalline cellulose 140mg     Diethylenetriaminepentaacetic acid-iron complex 10 mg     Glucosamine hydrochloride 50mg   Intravenous fat emulsion     Purified soybean phospholipid 10.0 mass%     Chitosan oligosaccharide 1.0% by mass     D-mannitol 5.0 mass%     Water for injection 84.0% by mass

【0049】[0049]

【発明の効果】以上説明したように、本発明によれば、
天然物由来の成分であるグルコサミン、重合度2〜10
のキトサンオリゴ糖、重合度11〜100の低分子キト
サン及びそれらの塩から選ばれた少なくとも1種を有効
成分として含有させることにより、効果的に一酸化窒素
を除去でき、摂取しても副作用等のない安全性の高い一
酸化窒素消去剤を提供できる。この一酸化窒素消去剤
は、飲食品、化粧品、医薬品等に好適に用いることがで
きる。特に、グルコサミン及び/又はその塩を含有する
一酸化窒素消去剤は、タバコ用フィルター、空気清浄器
やエアコンディショナー用フィルター等の成分として好
適に用いることができる。
As described above, according to the present invention,
Glucosamine, a natural product-derived component, polymerization degree: 2 to 10
Chitosan oligosaccharide, low molecular weight chitosan having a degree of polymerization of 11 to 100, and salts thereof as an active ingredient, nitric oxide can be effectively removed, and side effects even when ingested It is possible to provide a highly safe nitric oxide scavenger. This nitric oxide scavenger can be suitably used for foods, drinks, cosmetics, pharmaceuticals and the like. In particular, a nitric oxide scavenger containing glucosamine and / or a salt thereof can be preferably used as a component of a filter for tobacco, an air purifier, a filter for an air conditioner, or the like.

【図面の簡単な説明】[Brief description of drawings]

【図1】 各被験物質のNO消去能の試験結果を示す図
表である。
FIG. 1 is a table showing the test results of NO scavenging ability of each test substance.

【図2】 各フィルターの、タバコの煙中のNO消去能
の測定結果を示す図表である。
FIG. 2 is a table showing the measurement results of NO scavenging ability in cigarette smoke of each filter.

───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 FI テーマコート゛(参考) A61K 7/02 A61K 31/7016 31/7016 31/702 31/702 31/722 31/722 A61P 3/10 A61P 3/10 9/00 9/00 11/06 11/06 25/00 25/00 29/00 29/00 39/02 39/02 43/00 121 43/00 121 C07H 5/06 // C07H 5/06 A23L 2/00 F Fターム(参考) 4B017 LC03 LK13 4B018 MD41 ME14 4C057 BB02 CC04 DD02 4C083 AA112 AC122 AD201 AD202 AD321 AD332 AD572 CC12 4C086 EA02 EA23 MA02 MA35 MA52 MA66 NA14 ZC37 ZC75 ─────────────────────────────────────────────────── ─── Continuation of front page (51) Int.Cl. 7 Identification code FI theme code (reference) A61K 7/02 A61K 31/7016 31/7016 31/702 31/702 31/722 31/722 A61P 3/10 A61P 3/10 9/00 9/00 11/06 11/06 25/00 25/00 29/00 29/00 39/02 39/02 43/00 121 43/00 121 C07H 5/06 // C07H 5 / 06 A23L 2/00 FF term (reference) 4B017 LC03 LK13 4B018 MD41 ME14 4C057 BB02 CC04 DD02 4C083 AA112 AC122 AD201 AD202 AD321 AD332 AD572 CC12 4C086 EA02 EA23 MA02 MA35 MA52 MA66 NA14 ZC37 ZC75

Claims (4)

【特許請求の範囲】[Claims] 【請求項1】 グルコサミン、重合度2〜10のキトサ
ンオリゴ糖、重合度11〜100の低分子キトサン及び
それらの塩から選ばれた少なくとも1種を有効成分とし
て含有することを特徴とする一酸化窒素消去剤。
1. A monoxide containing at least one selected from glucosamine, chitosan oligosaccharides having a degree of polymerization of 2 to 10, low molecular weight chitosan having a degree of polymerization of 11 to 100, and salts thereof as an active ingredient. Nitrogen erasing agent.
【請求項2】 飲食品、医薬品、又は化粧品から選ばれ
た1種に添加して用いられる、請求項1に記載の一酸化
窒素消去剤。
2. The nitric oxide scavenger according to claim 1, which is used by adding it to one kind selected from foods and drinks, pharmaceuticals, or cosmetics.
【請求項3】 硝酸塩又は亜硝酸塩系の発色剤又は保存
剤を含有する飲食品に添加される、請求項2に記載の一
酸化窒素消去剤。
3. The nitric oxide scavenger according to claim 2, which is added to a food or drink containing a nitrate or nitrite type color former or a preservative.
【請求項4】 グルコサミン及び/又はその塩を有効成
分として含有し、タバコ用フィルター、空気清浄器用フ
ィルター、エアコンディショナー用フィルター又は自動
車のマフラー用フィルターから選ばれた1種の成分とし
て用いられる、請求項1に記載の一酸化窒素消去剤。
4. A composition containing glucosamine and / or a salt thereof as an active ingredient and used as one kind of component selected from a filter for cigarette, a filter for air purifier, a filter for air conditioner and a filter for muffler of an automobile. Item 2. A nitric oxide scavenger according to Item 1.
JP2001337858A 2001-11-02 2001-11-02 Nitric oxide scavenger Expired - Fee Related JP4373634B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2001337858A JP4373634B2 (en) 2001-11-02 2001-11-02 Nitric oxide scavenger

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001337858A JP4373634B2 (en) 2001-11-02 2001-11-02 Nitric oxide scavenger

Publications (2)

Publication Number Publication Date
JP2003137789A true JP2003137789A (en) 2003-05-14
JP4373634B2 JP4373634B2 (en) 2009-11-25

Family

ID=19152435

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001337858A Expired - Fee Related JP4373634B2 (en) 2001-11-02 2001-11-02 Nitric oxide scavenger

Country Status (1)

Country Link
JP (1) JP4373634B2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006011486A1 (en) * 2004-07-27 2006-02-02 Japan Tobacco Inc. Filter for cigarette and cigarette having same
JP2006521297A (en) * 2003-03-27 2006-09-21 サード ミリタリー メディカル ユニバーシティー,チャイニーズ ピープルズ リベレイション アーミー,ピー.アール.オブ チャイナ Use of N-acetyl-D-glucosamine in the treatment of organ damage caused by poisoning symptoms caused by drugs or toxicants
JP2007217304A (en) * 2006-02-14 2007-08-30 Yaizu Suisankagaku Industry Co Ltd Ultraviolet absorbing agent, skin preparation for external use containing the same, and antioxidant
WO2007125832A1 (en) * 2006-04-25 2007-11-08 Fancl Corporation Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing helipyrone a
KR100807432B1 (en) * 2004-07-27 2008-02-25 니뽄 다바코 산교 가부시키가이샤 Cigarette filter and cigarette provided with the same
JP2008179587A (en) * 2007-01-26 2008-08-07 Juntendo Inhibitor of expression of adhesion molecule in vascular endothelial cell and production of monocyte chemoattractant protein-1
CN102920020A (en) * 2012-11-16 2013-02-13 湖南中烟工业有限责任公司 Glucosamine loaded cigarette filter stick additive, as well as preparation and application methods thereof

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521297A (en) * 2003-03-27 2006-09-21 サード ミリタリー メディカル ユニバーシティー,チャイニーズ ピープルズ リベレイション アーミー,ピー.アール.オブ チャイナ Use of N-acetyl-D-glucosamine in the treatment of organ damage caused by poisoning symptoms caused by drugs or toxicants
JP4671954B2 (en) * 2003-03-27 2011-04-20 サード ミリタリー メディカル ユニバーシティー,チャイニーズ ピープルズ リベレイション アーミー,ピー.アール.オブ チャイナ Use of N-acetyl-D-glucosamine in the treatment of organ damage caused by poisoning symptoms caused by drugs or toxicants
WO2006011486A1 (en) * 2004-07-27 2006-02-02 Japan Tobacco Inc. Filter for cigarette and cigarette having same
KR100807432B1 (en) * 2004-07-27 2008-02-25 니뽄 다바코 산교 가부시키가이샤 Cigarette filter and cigarette provided with the same
JP2007217304A (en) * 2006-02-14 2007-08-30 Yaizu Suisankagaku Industry Co Ltd Ultraviolet absorbing agent, skin preparation for external use containing the same, and antioxidant
WO2007125832A1 (en) * 2006-04-25 2007-11-08 Fancl Corporation Singlet oxygen scavenger, anti-skin-aging agent, anti-wrinkle agent, anti-sagging agent, agent for improving moisture content in the skin, skin-whitening agent, melanin formation inhibitor, nitrogen monooxide scavenger and antioxidant, each utilizing helipyrone a
CN102626373A (en) * 2006-04-25 2012-08-08 株式会社芳珂 Agent for improving moisture content using Helipyrone A
TWI383793B (en) * 2006-04-25 2013-02-01 Fancl Corp A skin oxidative agent, a skin whitening improving agent, a wrinkle improving agent, a skin relaxation improving agent, a skin water content improving agent, a whitening agent, a melanin inhibitor, a nitric oxide eliminating agent, and an oxidative prevention agent agent
JP5266046B2 (en) * 2006-04-25 2013-08-21 株式会社ファンケル Wrinkle improver, sag improver, skin moisture content improver, whitening agent, melanin inhibitor made of helipyrone A
JP2008179587A (en) * 2007-01-26 2008-08-07 Juntendo Inhibitor of expression of adhesion molecule in vascular endothelial cell and production of monocyte chemoattractant protein-1
CN102920020A (en) * 2012-11-16 2013-02-13 湖南中烟工业有限责任公司 Glucosamine loaded cigarette filter stick additive, as well as preparation and application methods thereof

Also Published As

Publication number Publication date
JP4373634B2 (en) 2009-11-25

Similar Documents

Publication Publication Date Title
AU2008238445B2 (en) Extract of Trigonella foenum-graecum
Lundberg et al. Intragastric nitric oxide production in humans: measurements in expelled air.
JP3875733B2 (en) Body acetaldehyde metabolism promoter and method for producing the same
US5559152A (en) Pharmaceutical composition having antiacoholic activity
JP4373634B2 (en) Nitric oxide scavenger
US20020002136A1 (en) Salts of glutathione
JP3334725B2 (en) Accelerator for reducing alcohol in the body, its metabolites and oral freshener
JPH0614746A (en) Health beverage
JP2023519888A (en) Drugs for treating coronavirus and retroviral infections and hepatitis C
Lockey et al. Effect of oral activated charcoal on quinine elimination.
JP3884611B2 (en) Improving agent for impulsive disease
JP2002265365A (en) Neutrophil function inhibitor
WO2005096717A2 (en) Agent exhibiting hepatoprotective properties
JP2009505992A (en) Drunkenness reducing composition comprising hyaluronic acid and activated carbon
JP2000256196A (en) Anti-inflammatory and anti-allergic medicine
JP5546833B2 (en) Acetaldehyde / ethanol reducing agent
Rappolt Sr et al. NAGD regimen for the coma of drug-related overdose
CN113951515A (en) Preparation method of blood vessel endothelial cell bioactive lycium barbarum amino acid and lycium barbarum amino acid
JPH08277221A (en) Suppressant for alcohol absorption
US20200338153A1 (en) Anaerobic antioxidant composition
RU2160586C1 (en) Biologically active admixture of general strengthening action
JP2016514120A (en) Composition for oral administration for binding aldehydes in the gastrointestinal tract
JPH0940568A (en) Suppressing agent against caffeine excitation
JP3380287B2 (en) Beverages that increase blood alcohol levels
JPH06199692A (en) Agent for amelioration and treatment of cataract

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041026

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080624

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080825

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090324

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20090525

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20090825

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20090904

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120911

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees